NeoBOMB1 - Advanced Accelerator Applications

Drug Profile

NeoBOMB1 - Advanced Accelerator Applications

Alternative Names: 177Lu-NeoBOMB1; 68Ga-NeoBOMB1

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Erasmus University Rotterdam; National Center for Scientific Research Demokritos
  • Developer Advanced Accelerator Applications; Erasmus University Rotterdam; National Center for Scientific Research Demokritos
  • Class Imaging agents; Neuropeptides; Organometallic compounds; Peptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Bombesin receptor antagonists; Ionising radiation emitters; Neuropeptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
  • Phase I/II Gastrointestinal stromal tumours

Most Recent Events

  • 12 Feb 2018 Phase-II clinical trials in Non-small cell lung cancer (Diagnosis) in Austria (IV) (EudraCT2017-003432-37)
  • 12 Feb 2018 Preclinical trials in Breast cancer in Austria (IV) (Advanced Accelerator Applications pipeline, February 2018)
  • 12 Feb 2018 Preclinical trials in Gastrointestinal stromal tumours in Austria (IV) (Advanced Accelerator Applications pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top